The purpose of this study is to evaluate a novel VRP.
The primary objective of this study is to determine whether the subjective experience of a novel VRP (DeepDream) will be comparable to a standard dose of psychedelics. This study also looks to compare the subjective experience of DeepDream VRP to other available VR modalities developed to mimic psychedelic subjective experience along with assessing the incidence of VRP adverse effects.
Study Type
OBSERVATIONAL
Enrollment
15
Meta Quest 3 is a virtual reality headset device
Yale University School of Medicine
New Haven, Connecticut, United States
RECRUITINGAssess subjective experience of novel VRP (DeepDream) comparable to a standard dose of psychedelics.
Subject experience will be assessed using the Altered States of Consciousness Rating Scale.
Time frame: Day 0 through Day 30
Assess subjective experience of novel VRP (DeepDream) comparable to a standard dose of psychedelics.
Subject experience will be assessed using the Mystical Experience Questionnaire.
Time frame: Day 0 through Day 30
Assess subjective experience of novel VRP (DeepDream) comparable to a standard dose of psychedelics.
Subject experience will be assessed using the Ego-Dissolution Inventory.
Time frame: Day 0 through Day 30
Assess the incidence of VRP adverse effects, principally virtual reality sickness (VRS) and neck and upper back pain.
The number of adverse events will be assessed through qualitative interviews following VRP viewing.
Time frame: Day 0 through Day 30
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.